Vetivex 18 (Sodium Chloride 0.18% w/v and Glucose 4% w/v Intravenous Infusion B.P. (Vet))

Land: Vereinigtes Königreich

Sprache: Englisch

Quelle: VMD (Veterinary Medicines Directorate)

Wirkstoff:

Glucose, Sodium Chloride

Verfügbar ab:

Dechra Limited

ATC-Code:

QB05BB02

INN (Internationale Bezeichnung):

Glucose, Sodium Chloride

Darreichungsform:

Solution for infusion

Verschreibungstyp:

POM-V - Prescription Only Medicine – Veterinarian

Therapiegruppe:

Cats, Cattle, Dogs, Horses

Therapiebereich:

Replacement Agent

Berechtigungsstatus:

Authorized

Berechtigungsdatum:

1998-12-09

Fachinformation

Revised: June 2016
AN: 01534/2015
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetivex 18
(Sodium chloride 0.18 % w/v and Glucose 4 % w/v intravenous solution
for
infusion BP (Vet))
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substances:
Sodium chloride
0.18 % w/v
Glucose monohydrate
4.4 % w/v
(equivalent to anhydrous glucose 4.0 % w/v)
Approximate ionic content in millimoles per litre:
Sodium
30 mmol/L
Chloride
30 mmol/L
Each one litre provides approximately 150 kcal.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for Infusion
Clear, colourless solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, calves, horses, dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
This product is administered by intravenous infusion for maintenance
therapy
of dehydration in cattle, calves, horses, dogs and cats. It should be
used once
the underlying fluid balance has been restored.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Revised: June 2016
AN: 01534/2015
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Sodium overload may occur in animals with cardiac or renal impairment.
It
should be noted that sodium excretion may be impaired
post-surgery/trauma.
Administration of this product to diabetic animals must be conducted
with
extreme caution.
The solution should ideally be warmed to approximately 37
o
C prior to the
administration of large volumes, or if the administration rate is
high, in order to
avoid hypothermia.
This product should not be used for prolonged periods of time unless
there is
continuing excessive loss of electrolytes, as it may provoke
hypokalaemia.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
MEDICINAL PRODUCT TO ANIMALS
Not applicable.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
There is a risk of thrombosis with intravenous infusion.
Excessive infusion rates can cause restlessness, moist lung sounds,
tachycar